Search
IL15-NK Cell
go.drugbank.com/drugs/DB15725InvestigationalIn particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalIt acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.
SR-123781A
go.drugbank.com/drugs/DB05361InvestigationalSR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Mepiprazole
go.drugbank.com/drugs/DB09197ExperimentalLike other phenylpiperazine drugs, mepiprazole produces the active metabolite m-chlorophenylpiperazine(mCPP). … Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816]. Mepiprazole is marketed in Spain for the treatment of anxiety neuroses.
Edotecarin
go.drugbank.com/drugs/DB04882InvestigationalEdotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.
Cyclic GMP
go.drugbank.com/drugs/DB02315ExperimentalIts levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) … Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions.
Ibopamine
go.drugbank.com/drugs/DB13316ExperimentalCategories: Compounds used in a research, industrial, or household settingTelavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalMRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant